Bupivacaine-induced Vasodilation Is Mediated by Decreased Calcium Sensitization in Isolated Endothelium-denuded Rat Aortas Precontracted with Phenylephrine

1Department of Anesthesiology and Pain Medicine, Institute of Health Sciences, Gyeongsang National University School of Medicine, Gyeongsang National University Hospital, Jinju, Korea
2Department of Anesthesiology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea
3Department of Physiology, Kwandong University College of Medicine, Gangneung, Korea
4Department of Anesthesiology and Pain Medicine, Gyeongsang National University Hospital, Jinju, Korea
5Department of Oral and Maxillofacial Surgery, Gyeongsang National University Hospital, Jinju, Korea

Seong Ho Ok1,*, Sung Il Bae2,*, Seong Chun Kwon3, Jung Chul Park4, Woo Chan Kim4, Kyeong Eon Park4, Il Woo Shin1, Heon Keun Lee1, Young Kyun Chung1, Mun Jeoung Choi5, and Ju Tae Sohn1

Background:
A toxic dose of bupivacaine produces vasodilation in isolated aortas. The goal of this in vitro study was to investigate the cellular mechanism associated with bupivacaine-induced vasodilation in isolated endothelium-denuded rat aortas precontracted with phenylephrine.

Methods:
Isolated endothelium-denuded rat aortas were suspended for isometric tension recordings. The effects of nifedipine, verapamil, iberiotoxin, 4-aminopyridine, barium chloride, and glibenclamide on bupivacaine concentration-response curves were assessed in endothelium-denuded aortas precontracted with phenylephrine. The effect of phenylephrine and KCl used for precontraction on bupivacaine-concentration-response curves was assessed. The effects of verapamil on phenylephrine concentration-response curves were assessed. The effects of bupivacaine on the intracellular calcium concentration ([Ca2+]i) and tension in aortas precontracted with phenylephrine were measured simultaneously with the acetoxymethyl ester of a fura-2-loaded aortic strip.

Results:
Pretreatment with potassium channel inhibitors had no effect on bupivacaine-induced relaxation in the endothelium-denuded aortas precontracted with phenylephrine, whereas verapamil or nifedipine attenuated bupivacaine-induced relaxation. The magnitude of the bupivacaine-induced relaxation was enhanced in the 100 mM KCl-induced precontracted aortas compared with the phenylephrine-induced precontracted aortas. Verapamil attenuated the phenylephrine-induced contraction. The magnitude of the bupivacaine-induced relaxation was higher than that of the bupivacaine-induced [Ca2+]i decrease in the aortas precontracted with phenylephrine.
Conclusions:

Taken together, these results suggest that toxic-dose bupivacaine-induced vasodilation appears to be mediated by decreased calcium sensitization in endothelium-denuded aortas precontracted with phenylephrine. In addition, potassium channel inhibitors had no effect on bupivacaine-induced relaxation. Toxic-dose bupivacaine-induced vasodilation may be partially associated with the inhibitory effect of voltage-operated calcium channels. (Korean J Pain 2014; 27: 229-238)

Key Words:
aorta, bupivacaine, calcium sensitization, phenylephrine, vasodilation, verapamil.
the bath solution was changed every 30 min. The endothelium was removed from the aortic rings by inserting a 25-gauge needle tip into the lumen of the rings and gently rubbing the ring for a few seconds. As soon as the phenylephrine (10^{-8} M)-induced contraction had stabilized, endothelial removal was confirmed by the observation of less than 10% relaxation in response to acetylcholine (10^{-5} M). After washing out the phenylephrine from the organ bath and allowing for the return of isometric tension to the baseline resting tension, the main experiment was performed as described in the experimental protocols. The contractile response induced by isotonic 60 mM KCl was measured in an endothelium-denuded aortic ring used for phenylephrine concentration–response curves, and it was used as a reference value to express the magnitude of the contractile response induced by the cumulative addition of phenylephrine. In the main experiments involving only the endothelium-denuded aortas, the Krebs solution also contained the nitric oxide synthase inhibitor N^w-nitro-L-arginine methyl ester (L-NAME, 10^{-4} M) to prevent the release of endogenous nitric oxide from any residual endothelium [6,7,9].

2. Experimental protocol

First, the effects of various potassium channel inhibitors on bupivacaine concentration–response curves in the endothelium-denuded aortas precontracted with phenylephrine were assessed. Glibenclamide (10^{-5} M), an adenosine triphosphate-sensitive potassium channel inhibitor, or iberiotoxin (10^{-7} M), a large conductance voltage-dependent potassium channel inhibitor, were added directly to the organ bath for 20 min before the addition of phenylephrine (10^{-7} M). Because pretreatment with the voltage–dependent potassium channel inhibitor 4-aminopyridine (2 × 10^{-3} M) or the inward rectifying potassium channel inhibitor barium chloride (3 × 10^{-5} M) shifted upward the baseline resting tension for the incubation period before the addition of phenylephrine, we added 4-aminopyridine (2 × 10^{-3} M) or barium chloride (3 × 10^{-5} M) into the organ bath about 3 min after the addition of phenylephrine (10^{-7} M). We then waited for about 30 min so that the phenylephrine–induced contraction could plateau. After the phenylephrine (10^{-7} M)–induced contraction had stabilized, incremental concentrations (5.36 × 10^{-7} to 9.51 × 10^{-4} M) of bupivacaine were added to the organ bath to generate bupivacaine concentration–response curves. The effect of various potassium channel inhibitors on the bupivacaine concentration (5.36 × 10^{-7} to 9.51 × 10^{-4} M)–response curves was assessed by comparing the bupivacaine–induced vasorelaxant response in the presence or absence of each potassium channel inhibitor. Concentrations of various potassium channel inhibitors were chosen on the basis of the concentrations used in previous experiments similar to this experiment [11,16–18].

Second, the effect of voltage-operated calcium channel inhibitors on the bupivacaine concentration–response curves in endothelium-denuded aortas precontracted with phenylephrine (3 × 10^{-6} M) was assessed. The voltage–operated calcium channel inhibitors nifedipine (10^{-9}, 10^{-8} and 10^{-7} M) and verapamil (10^{-6} and 10^{-5} M) were added to the organ bath for 20 min before the addition of phenylephrine (3 × 10^{-6} M) [7]. After the phenylephrine (3 × 10^{-6} M)–induced contraction had stabilized, incremental concentrations of bupivacaine were added to the organ bath to generate bupivacaine concentration–response curves. The effects of the voltage–operated calcium channel inhibitors on the bupivacaine concentration–response curves were assessed by comparing the bupivacaine–induced vasorelaxant response in the presence or absence of either verapamil or nifedipine.

Third, we assessed the bupivacaine concentration–response curves in endothelium-denuded aortas precontracted with phenylephrine (3 × 10^{-6} M) or 100 mM KCl to examine whether the magnitude of the relaxant response induced by bupivacaine is dependent on the contractile agonist (phenylephrine or KCl) used for precontraction of the endothelium-denuded aortas before the cumulative addition of bupivacaine. After phenylephrine (3 × 10^{-6} M) or 100 mM KCl had produced a stable and sustained contraction, bupivacaine was added directly to the organ bath to produce cumulative bupivacaine concentration–response curves.

Finally, the effects of verapamil (10^{-5} and 10^{-6} M) on the phenylephrine concentration (10^{-9} to 10^{-5} M)–response curves were assessed to examine whether phenylephrine–induced contraction involves the activation of voltage–operated calcium channels. Verapamil (10^{-5} and 10^{-6} M) was added to the organ bath for 20 min before the addition of phenylephrine. Incremental concentrations of phenylephrine (10^{-9} to 10^{-5} M) were cumulatively added to the organ bath to generate phenylephrine concentration–response curves in the presence or absence of verapamil.
3. Fura-2 loading and simultaneous measurement of intracellular calcium concentration \([\text{Ca}^{2+}]_i\), and tension

\([\text{Ca}^{2+}]_i\), was measured according to the method described by Shim et al. [6] using the fluorescent \(\text{Ca}^{2+}\) indicator fura-2. Muscle strips were exposed to the acetoxymethyl ester of fura-2 (fura-2/AM, 10 μM) in the presence of 0.02% cremophor EL for 5–6 h at room temperature. After loading, a muscle strip was washed with Krebs solution at 37°C for 20 min to remove any uncleaved fura-2/AM and held horizontally in a temperature-controlled, 7 ml organ bath. One end of the muscle strip was connected to a force-displacement transducer (MLT050, AD Instruments, Colorado Springs, CO, USA) to monitor the muscle contraction. The muscle strip was illuminated alternately (48 Hz) at two excitation wavelengths (340 and 380 nm). The intensity of 500 nm fluorescence (F340 and F380) was measured with a fluorometer (CAF-110, Jasco, Tokyo). The ratio of F340 to F380 (F340/F380) was calculated as an indicator of \([\text{Ca}^{2+}]_i\). The absolute \(\text{Ca}^{2+}\) concentration was not calculated in this experiment because the dissociation constant of the fluorescence indicator for \(\text{Ca}^{2+}\) in cytosol may be different from that obtained in vitro [19]. Therefore, the ratio (F340/F380) and tension obtained from either 3 × 10⁻⁶ M phenylephrine or 100 mM KCl-stimulated aortic strips were taken as 100 and 100%, respectively. Isometric contractions and the ratio of F340/F380 were recorded with a PowerLab/400 using the chart program (AD instruments). Muscle strips were placed under an initial 3.0-g resting tension. All strips that came from the same animal were used in a different experimental protocol. When 100 mM KCl- or 3 × 10⁻⁶ M phenylephrine-stimulated \([\text{Ca}^{2+}]_i\), and contraction reached steady state levels, various bupivacaine contents (5.36 × 10⁻⁷, 1.61 × 10⁻⁵, 5.36 × 10⁻⁵, 2.52 × 10⁻⁴ and 9.51 × 10⁻⁶ M) were added cumulatively.

4. Drugs

All drugs were of the highest purity available commercially. Verapamil, nifedipine, 4-aminoopyridine, barium chloride, glibenclamide, acetylcholine, L-NAME, and phenylephrine were obtained from Sigma–Aldrich (St. Louis, MO, USA). Bupivacaine was obtained from Reyon Pharmaceutical Co., Ltd. (Seoul, Korea). Iberiotoxin was obtained from Tocris Bioscience (Bristol, United Kingdom). Fura-2/AM was obtained from Molecular Probes (Eugene, OR, USA). All concentrations are expressed as the final molar concentration in the organ bath. Glibenclamide, nifedipine, and fura-2/AM were dissolved in dimethyl sulfoxide (DMSO) (final organ bath concentration: 0.1% DMSO). Unless stated otherwise, all drugs were dissolved in distilled water.

5. Data analysis

Values are expressed as the mean ± SD. N indicates the number of isolated descending thoracic aortic rings. Relaxant responses to bupivacaine in endothelium-denuded aortas precontracted with phenylephrine (10⁻⁷ or 3 × 10⁻⁶ M) or 100 mM KCl are expressed as the percentage of the baseline precontraction induced by phenylephrine (10⁻⁷ or 3 × 10⁻⁶ M) or 100 mM KCl. Contractile responses to phenylephrine in endothelium-denuded aortas with resting tension are expressed as the percentage of the maximum contractile response induced by isotonic 60 mM KCl. The relaxant response and \([\text{Ca}^{2+}]_i\) decrease induced by bupivacaine are expressed as the percentage of the maximal contraction and \([\text{Ca}^{2+}]_i\) induced by phenylephrine or KCl, respectively. The effects of potassium or calcium channel inhibitors on bupivacaine-induced concentration-response curves and phenylephrine-induced concentration-response curves were analyzed with two-way repeated measure analysis of variance followed by the Bonferroni post-test (Prism 5.0, GraphPad Software, San Diego, CA, USA). The effect of contractile agonists (phenylephrine or KCl) on bupivacaine-induced concentration-response curves was analyzed with two-way repeated measure analysis of variance followed by the Bonferroni post-test. The relaxant response and \([\text{Ca}^{2+}]_i\) decrease with each concentration of bupivacaine were analyzed using repeated measures analysis of variance (ANOVA) followed by the Bonferroni post-test. Comparison between tension and \([\text{Ca}^{2+}]_i\) induced by the cumulative addition of bupivacaine was performed using two-way repeated measure analysis of variance followed by the Bonferroni post-test. \(P\) values less than 0.05 were considered significant.
10−5 M) had no effect on bupivacaine-induced relaxation in isolated endothelium-denuded aortas precontracted with phenylephrine (10−7 M) (Fig. 1).

Verapamil (10−6 and 10−5 M) and nifedipine (10−9, 10−8, and 10−7 M) attenuated bupivacaine-induced relaxation in endothelium-denuded aortas precontracted with 3 × 10−6 M phenylephrine in a concentration-dependent manner (verapamil: P < 0.001 versus control at 5.36 × 10−5 and 2.52 × 10−4 M bupivacaine; nifedipine: P < 0.001 versus control at 2.52 × 10−4 M bupivacaine) (Fig. 2).

The magnitude of bupivacaine-induced relaxation was higher in endothelium-denuded aortas precontracted with 100 mM KCl than in those precontracted with 3 × 10−6 M phenylephrine (P < 0.01 at 1.61 × 10−5 to 2.52 × 10−4 M bupivacaine) (Fig. 3).

Verapamil (10−5 and 10−6 M) attenuated phenyl-
Fig. 2. The effects of verapamil ($10^{-6}$ and $10^{-5}$ M; A) and nifedipine ($10^{-9}$, $10^{-8}$ and $10^{-7}$ M; B) on bupivacaine-induced concentration-response curves in isolated endothelium-denuded aortas precontracted with $3 \times 10^{-6}$ M phenylephrine. Data are the means ± SD expressed as the percentage of the maximal contraction induced by phenylephrine (100% = 2.42 ± 0.61 g [n = 6], 100% = 2.02 ± 0.41 g [n = 5], and 100% = 1.85 ± 0.38 g [n = 5] for endothelium-denuded rings with control, $10^{-6}$ M verapamil, and $10^{-5}$ M verapamil, respectively, in A; 100% = 2.81 ± 0.65 g [n = 8], 100% = 3.06 ± 0.45 g [n = 7], 100% = 3.01 ± 0.41 g [n = 6], and 100% = 2.50 ± 0.77 g [n = 6] for endothelium-denuded rings with control, $10^{-9}$ M nifedipine, $10^{-8}$ nifedipine, and $10^{-7}$ M nifedipine, respectively, in B). N indicates the number of isolated descending thoracic aortic rings. *$P < 0.001$, †$P < 0.05$, and ‡$P < 0.01$ versus control. §$P < 0.01$ versus $10^{-9}$ M nifedipine.

Fig. 3. Bupivacaine concentration-response curve in isolated endothelium-denuded aortas precontracted with $3 \times 10^{-6}$ M phenylephrine or 100 mM KCl. Data are the means ± SD expressed as the percentage of the maximal contraction induced by the contractile agonist (100% = 2.85 ± 0.59 [n = 8] and 100% = 2.68 ± 0.34 g [n = 8] for endothelium-denuded rings with 3 × 10^{-6} M phenylephrine and 100 mM KCl, respectively). N indicates the number of isolated descending thoracic aortic rings. *$P < 0.001$ and †$P < 0.01$ versus 3 × 10^{-6} M phenylephrine. ‡$P < 0.01$ and §$P < 0.001$ versus 5.36 × 10^{-7} M bupivacaine.

Fig. 4. The effects of verapamil ($10^{-6}$ and $10^{-5}$ M) on phenylephrine concentration-response curves in isolated endothelium-denuded aortas. Data are the means ± SD expressed as the percentage of the maximal contraction induced by isotonic 60 mM KCl (100% = 2.33 ± 0.45 g [n = 5], 100% = 2.78 ± 0.08 g [n = 5], and 100% = 2.67 ± 0.48 g [n = 5] for endothelium-denuded rings with control, $10^{-6}$ M verapamil and $10^{-5}$ M verapamil, respectively). N indicates the number of isolated descending thoracic aortic rings. *$P < 0.001$ versus control. †$P < 0.01$, ‡$P < 0.001$, and §$P < 0.05$ versus $10^{-6}$ M verapamil.
ephrine–induced contraction in a concentration–dependent manner \((P < 0.001\) versus control at \(10^{-6}\) to \(10^{-5}\) M bupivacaine, Fig. 4).

In aortas precontracted with phenylephrine, bupivacaine produced vasodilation \((P < 0.05\) versus \(3 \times 10^{-6}\) M phenylephrine) and decreased \([Ca^{2+}]\) \((P < 0.001\) versus \(3 \times 10^{-6}\) M phenylephrine) (Fig. 5). The magnitude of the bupivacaine–induced relaxation was higher than that of the bupivacaine–induced \([Ca^{2+}]\) decrease in aortas precontracted with phenylephrine \((P < 0.001\) at \(2.52 \times 10^{-4}\) and \(9.51 \times 10^{-4}\) M bupivacaine; Fig. 5B). In aortas precontracted with KCl, bupivacaine produced vasodilation \((P < 0.05\) versus 100 mM KCl) and decreased \([Ca^{2+}]\) \((P < 0.01\) versus 100 mM KCl) (Fig. 6). The magnitude of the bupivacaine–induced relaxation was not significantly different from that of the bupivacaine–induced \([Ca^{2+}]\) decrease in the aortas precontracted with KCl (Fig. 6B).

**DISCUSSION**

This study provides new evidence to suggest that bupivacaine–induced vasodilation in isolated rat aortas precontracted with phenylephrine appears to be associated with the inhibition of calcium sensitization. The major findings of this *in vitro* study are as follows: 1) the magnitude of the bupivacaine–induced relaxation was higher than that of the bupivacaine–induced \([Ca^{2+}]\) decrease in aortas precontracted with phenylephrine, suggesting decreased calcium sensitization; 2) verapamil and nifedipine attenuated bupivacaine–induced relaxation; 3) the magnitude of the bupivacaine–induced relaxation was higher in 100 mM KCl–precontracted aortas than in phenylephrine–induced precontracted aortas; and 4) potassium channel inhibitors had no effect on bupivacaine–induced relaxation.

The stimulation of potassium channels leads to potassium efflux and subsequently induces membrane hyperpolarization, which promotes vasorelaxation via inhibition of calcium influx through voltage–operated calcium channels [11,20]. The activation of potassium channels, including large conductance calcium–activated and voltage–dependent potassium channels, by membrane depolarization...
Fig. 6. (A) Effect of bupivacaine on high KCl (100 mM)-stimulated intracellular calcium concentration ([Ca\(^{2+}\)]) (upper trace) and muscle tension (lower trace) in endothelium-denuded rat thoracic aortas. The [Ca\(^{2+}\)] of fura-2-loaded aortic strips was detected using a fluorometer and expressed as the ratio F340/F380. 100% represents the 100 mM KCl-induced increases in both [Ca\(^{2+}\)] and muscle tension before the cumulative addition of bupivacaine. When the [Ca\(^{2+}\)] and muscle tension induced by high KCl reached a steady state level, various bupivacaine contents (5.36 × 10^{-6}, 1.61 × 10^{-5}, 5.36 × 10^{-5}, 2.52 × 10^{-4} and 9.51 × 10^{-4} M) were cumulatively added. (B) Concentration-inhibition curve for bupivacaine in high KCl (100 mM)-stimulated endothelium-denuded rat thoracic aortas. Various bupivacaine contents were cumulatively applied during the sustained increases in both [Ca\(^{2+}\)] and tension induced by high KCl (100 mM). 100% represents 100 mM KCl-induced increase in both [Ca\(^{2+}\)] and muscle tension before the cumulative addition of bupivacaine. Each point represents the mean of 5 experiments, and SD is shown by vertical bars. *P < 0.05, †P < 0.001 and ‡P < 0.01 versus 100 mM KCl.

tion induced by a contractile agonist limits vasoconstriction as a negative feedback mechanism [20]. Pretreatment with iberiotoxin or 4-aminopyridine had no effect on the bupivacaine-induced relaxation in isolated endothelium-denuded aortas precontracted with phenylephrine, suggesting that bupivacaine-induced relaxation does not involve the activation of large conductance calcium-activated and voltage-dependent potassium channels. In addition, glibenclamide and barium chloride had no effect on bupivacaine-induced relaxation, suggesting that bupivacaine-induced relaxation does not activate adenosine triphosphate-sensitive and inward rectifying potassium channels. However, the voltage-operated calcium channel inhibitors nifedipine and verapamil attenuated the bupivacaine-induced relaxation (Fig. 2), suggesting an inhibitory effect of bupivacaine on voltage-operated calcium channels. In previous studies using isolated rat aortas with resting tension, the magnitude of vasodilation induced by the toxic dose (3 × 10^{-4} M) of levobupivacaine was attenuated by verapamil or nifedipine, suggesting that toxic-dose levobupivacaine-induced vasodilation may involve the inhibition of voltage-operated calcium channels [7]. In addition, a single toxic dose of levobupivacaine (3 × 10^{-4} M) and bupivacaine (3 × 10^{-4} M) produces relaxation in isolated endothelium-denuded aortas precontracted with 60 mM KCl [4,8,10]. Furthermore, the toxic dose of levobupivacaine (10^{-4} and 3 × 10^{-4} M) inhibits 60 mM KCl-induced contraction [7].

In the present study, the magnitude of the bupivacaine-induced relaxation was strongly dependent on that of the bupivacaine-induced [Ca\(^{2+}\)] decrease in aortas precontracted with KCl (Fig. 6). Taking into consideration the previous reports and current results, bupivacaine (above 1.61 × 10^{-5} M)–induced relaxation appears to be associated with the inhibition of voltage-operated calcium channels [4,7,8,10]. Similar to the bupivacaine-induced relaxation observed in the current study, bupivacaine inhibits norepinephrine-induced contraction and induces vaso-relaxation in isolated vessels precontracted with nor-epinephrine [2,3]. However, as nifedipine or verapamil did not completely abolish bupivacaine-induced relaxation in the current study, further studies are required on other cellular mechanisms of bupivacaine-induced relaxation besides the inhibition of voltage-operated calcium channels.
Smooth muscle contraction is regulated by a calcium-dependent mechanism associated with $[Ca^{2+}]$. Therefore, the inhibitory effect of bupivacaine does not appear to be limited to a decrease in $[Ca^{2+}]$. In the present study using simultaneous $[Ca^{2+}]$ and tension measurement, the magnitude of bupivacaine-induced relaxation was similar to that of the bupivacaine-induced $[Ca^{2+}]$ decrease in KCl-induced precontracted aortas (Fig. 6B), whereas the magnitude of bupivacaine-induced relaxation was higher than that of the bupivacaine-induced $[Ca^{2+}]$ decrease in phenylephrine-induced precontracted aortas (Fig. 5B). These results suggest that bupivacaine-induced relaxation may be associated with the inhibition of calcium sensitization involved in phenylephrine-induced contraction. In addition, Rho-kinase and protein kinase C inhibitors attenuate mepivacaine-induced vasoconstriction via the inhibition of calcium sensitization, suggesting that decreased calcium sensitization seems to be associated with vasodilation [15]. Because phenylephrine-induced contraction involves calcium sensitization associated with a pathway mediated by protein kinase C and Rho kinase, further research is needed regarding whether bupivacaine-induced vasodilation in aortas precontracted with phenylephrine may be associated with the inhibitory effect of bupivacaine on Rho-kinase- and protein kinase C-mediated calcium sensitization induced by Rho-kinase activator NaF or protein kinase C activator phorbol 12,13-dibutyrate [21].

KCl-induced contraction is mainly mediated by calcium influx via voltage-operated calcium channels [22]. Contraction induced by a receptor-mediated contractile agonist is mediated by calcium influx via receptor-operated calcium channels and calcium release from the sarcoplasmic reticulum [22]. In agreement with previous findings that verapamil attenuates phenylephrine-induced contraction and that norepinephrine-induced contraction involves calcium influx via both voltage- and receptor-operated calcium channels, verapamil attenuated phenylephrine-induced contraction (Fig. 4), suggesting that phenylephrine-induced contraction appears to involve partial activation of voltage-operated calcium channels [12,23]. In addition, norepinephrine-induced contraction involves the opening of verapamil-sensitive L-type calcium channels [22]. A supraclinical dose of alfentanil and etomidate attenuates phenylephrine-induced contraction via an inhibitory effect on calcium influx via voltage-operated calcium channels [12,13]. Taking into consideration previous reports and the current results, particularly our finding that the magnitude of bupivacaine-induced relaxation was more potent in endothelium-denuded aortas precontracted with 100 mM KCl than with phenylephrine ($3 \times 10^{-6} \text{ M}$) (Fig. 3), bupivacaine-induced relaxation in the current study appears to be mediated, in part, by the inhibition of voltage-operated calcium channels in endothelium-denuded aortas precontracted with phenylephrine [12,22,23]. Further studies are needed on the signal transduction pathway associated with the inhibition of voltage-operated calcium channels induced by a toxic dose of bupivacaine in vascular smooth muscle.

The clinical relevance of the current in vitro study should be tempered because of the following factors: 1) we used aortas as conduit vessels in this study, whereas organ blood flow is controlled by small resistance arterioles; 2) we used endothelium-denuded aortas, whereas endothelial nitric oxide release due to blood flow-induced shear stress in vivo could enhance toxic-dose bupivacaine-induced vasodilation; and 3) differences in species (rats versus humans) and experimental setting (in vitro versus in vivo) could modify the current results [24,25]. Even with these limitations, the concentration ($1.61 \times 10^{-5}$ to $9.51 \times 10^{-4} \text{ M}$) of bupivacaine that produced vasodilation exceeds the plasma concentration of bupivacaine ($6.4 \times 10^{-6}$ to $1.85 \times 10^{-5} \text{ M}$) required to produce myocardial depression due to bupivacaine-induced systemic toxicity; therefore, toxic-dose bupivacaine-induced vasodilation induced by the inhibition of calcium sensitization on vascular smooth muscle may contribute to cardiovascular collapse due to bupivacaine systemic toxicity [26].

In conclusion, toxic-dose bupivacaine-induced vasodilation seems to be mediated by the inhibition of calcium sensitization evoked by phenylephrine in isolated endothelium-denuded rat aortas. In addition, potassium channel inhibitors had no effect on bupivacaine-induced relaxation. Toxic-dose bupivacaine-induced relaxation appears to be partially associated with the inhibition of voltage-dependent calcium channel activated by phenylephrine in endothelium-denuded rat aortas.

**ACKNOWLEDGEMENTS**

This research was supported by the Basic Science Research Program through the National Research Found-
funded by the Ministry of Education, Science, and Technology (KRF-2011-0006783). This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2013R1A1A2057459).

REFERENCES

1. Beilin Y, Halpern S. Focused review: ropivacaine versus bupivacaine for epidural labor analgesia. Anesth Analg 2010; 111: 482–7.
2. Szocik JF, Gardner CA, Webb RC. Inhibitory effects of bupivacaine and lidocaine on adrenergic neurotransmitter junctions in rat tail artery. Anesthesiology 1993; 78: 911–7.
3. Hahnenkamp K, Nollet J, Struppler D, Halene T, Rathsman P, Mortier E, et al. Bupivacaine inhibits thromboxane A2–induced vasoconstriction in rat thoracic aorta. Anesth Analg 2004; 99: 97–102.
4. Ok SH, Park CS, Kim JH, Lee SH, Choi BH, Eun SY, et al. Effect of two lipid emulsions on reversing high-dose levobupivacaine-induced reduced vasoconstriction in the rat aorta. Cardiovasc Toxicol 2013; 13: 370–80.
5. Sung HJ, Ok SH, Sohn JY, Son YH, Kim JK, Lee SH, et al. Vasoconstriction potency induced by aminoamide local anesthetics correlates with lipid solubility. J Biomed Biotechnol 2012; 2012: 170958.
6. Shim HS, Ok SH, Lee SH, Kwon SC, Sohn JT. Protein kinases participate in the contraction in response to levobupivacaine in the rat aorta. Eur J Pharmacol 2012; 677: 131–7.
7. Baik JS, Sohn JT, Ok SH, Kim JG, Sung HJ, Park SS, et al. Levobupivacaine–induced contraction of isolated rat aorta is calcium dependent. Can J Physiol Pharmacol 2011; 89: 467–76.
8. Ok SH, Sohn JT, Baik JS, Kim JG, Park SS, Sung HJ, et al. Lipid emulsion reverses levobupivacaine–induced responses in isolated rat aortic vessels. Anesthesiology 2011; 114: 293–301.
9. Choi YS, Jeong YS, Ok SH, Shin MW, Lee SH, Park JY, et al. The direct effect of levobupivacaine in isolated rat aorta involves lipoxygenase pathway activation and endothelial nitric oxide release. Anesth Analg 2010; 110: 341–9.
10. Ok SH, Han JY, Lee SH, Shin MW, Lee HK, Chung YK, et al. Lipid emulsion–mediated reversal of toxic–dose aminoamide local anesthetic–induced vasodilation in isolated rat aorta. Korean J Anesthesiol 2013; 64: 353–9.
11. Ko EA, Han J, Jung ID, Park WS. Physiological roles of K+ channels in vascular smooth muscle cells. J Smooth Muscle Res 2008; 44: 65–81.
12. Shin IW, Sohn JT, Kim HJ, Kim C, Lee HK, Chang KC, et al. Elomidae attenuates phenylephrine–induced contraction in isolated rat aorta. Can J Anaesth 2005; 52: 927–34.
13. Sohn JT, Park KE, Kim C, Jeong YS, Shin IW, Lee HK, et al. Antitannin attenuates phenylephrine–induced contraction in rat aorta. Eur J Anaesthesiol 2007; 24: 276–82.
14. Akata T, Cellular and molecular mechanisms regulating vascular tone, Part 2: regulatory mechanisms modulating Ca2+ mobilization and/or myofilament Ca2+ sensitivity in vascular smooth muscle cells. J Anesth 2007; 21: 232–42.
15. Ok SH, Kwon SC, Yeol Han J, Yu J, Shin IW, Lee HK, et al. Mepivacaine–induced contraction involves increased calcium sensitization mediated via Rho kinase and protein kinase C in endothelium–denuded rat aorta. Eur J Pharmacol 2014; 723: 185–93.
16. Kaya T, Gursoy S, Karadas B, Sarac B, Fatahi H, Soydan AS. High–concentration tramadol–induced vasodilation in rabbit aorta is mediated by both endothelium–dependent and –independent mechanisms. Acta Pharmacol Sin 2003: 24: 385–9.
17. Subramaniam G, Achike FI, Mustafa MR. Effect of acidosis on the mechanism(s) of insulin–induced vasorelaxation in normal Wistar–Kyoto (WKY) rat aorta. Regul Pept 2009; 155: 70–5.
18. Xue YL, Shi HK, Murad F, Bian K. Vasodilatory effects of cinnamaldehyde and its mechanism of action in the rat aorta. Vasc Health Risk Manag 2011; 7: 273–80.
19. Karaki H. Ca2+ localization and sensitivity in vascular smooth muscle. Trends Pharmacol Sci 1989; 10: 320–5.
20. Thornseloe KS, Nelson MT. Ion channels in smooth muscle: regulators of intracellular calcium and contractility, Can J Physiol Pharmacol 2005; 83: 215–42.
21. Kilazawa T, Kilazawa K. Size–dependent heterogeneity of contractile Ca2+ sensitization in rat arterial smooth muscle, J Physiol 2012; 590: 5401–23.
22. Karaki H, Ozaki H, Hori M, Mitsur–Saito M, Amano K, Harada K, et al. Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev 1997; 49: 157–230.
23. Huang Y, Ho IH. Separate activation of intracellular Ca2+ release, voltage–dependent and receptor–operated Ca2+ channels in the rat aorta. Chin J Physiol 1996; 39: 1–8.
24. Christensen KL, Mulvaney MJ. Location of resistance arteries, J Vasc Res 2001; 38: 1–12.
25. Lu D, Kassab GS. Role of shear stress and stretch in vascular mechanobiology, J R Soc Interface 2011; 8: 1379–85.
26. Groban L, Deal DD, Vernon JC, James RL, Butterworth J. Does local anesthetic stereoselectivity or structure predict myocardial depression in anesthetized canines? Reg Anesth Pain Med 2002; 27: 460–8.